Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Blood ; 120(1): 112-21, 2012 Jul 05.
Article in English | MEDLINE | ID: mdl-22649103

ABSTRACT

Dendritic cells (DCs) are essential in inducing adaptive immune responses against bacteria by expressing cytokines that skew T-cell responses toward protective Th17 cells. Although it is widely recognized that induction of these cytokines by DCs involves activation of multiple receptors, it is still incompletely characterized which combination of receptors specifically skews Th17-cell responses. Here we have identified a novel role for FcγRIIa in promoting human Th17 cells. Activation of DCs by bacteria opsonized by serum IgG strongly promoted Th17 responses, which was FcγRIIa-dependent and coincided with enhanced production of selected cytokines by DCs, including Th17-promoting IL-1ß and IL-23. Notably, FcγRIIa stimulation on DCs did not induce cytokine production when stimulated individually, but selectively amplified cytokine responses through synergy with TLR2, 4, or 5. Importantly, this synergy is mediated at 2 different levels. First, TLR-FcγRIIa costimulation strongly increased transcription of pro-IL-1ß and IL-23p19. Second, FcγRIIa triggering induced activation of caspase-1, which cleaves pro-IL-1ß into its bioactive form and thereby enhanced IL-1ß secretion. Taken together, these data identified cross-talk between TLRs and FcγRIIa as a novel mechanism by which DCs promote protective effector Th17-cell responses against bacteria.


Subject(s)
Bacterial Infections/immunology , Dendritic Cells/immunology , Immunoglobulin G/immunology , Receptors, IgG/immunology , Th17 Cells/immunology , Toll-Like Receptors/immunology , Adaptive Immunity/immunology , Cell Communication/immunology , Cytokines/immunology , Cytokines/metabolism , Dendritic Cells/cytology , Dendritic Cells/microbiology , Escherichia coli/immunology , Escherichia coli Infections/immunology , Humans , Ligands , Macrophages/cytology , Macrophages/immunology , Macrophages/microbiology , Receptor Cross-Talk/immunology , Salmonella Infections/immunology , Salmonella typhimurium/immunology , Staphylococcal Infections/immunology , Staphylococcus aureus/immunology , Staphylococcus epidermidis/immunology , Th17 Cells/cytology , Th17 Cells/microbiology
2.
Blood ; 118(23): 6107-14, 2011 Dec 01.
Article in English | MEDLINE | ID: mdl-21926348

ABSTRACT

IL-17-producing CD4(+) T helper (Th17) cells are important for immunity against extracellular pathogens and in autoimmune diseases. The factors that drive Th17 development in human remain a matter of debate. Here we show that, compared with classic CD28 costimulation, alternative costimulation via the CD5 or CD6 lymphocyte receptors forms a superior pathway for human Th17-priming. In the presence of the Th17-promoting cytokines IL-1ß, IL-6, IL-23, and transforming growth factor-ß (TGF-ß), CD5 costimulation induces more Th17 cells that produce higher amounts of IL-17, which is preceded by prolonged activation of signal transducer and activator of transcription 3 (STAT3), a key regulator in Th17 differentiation, and enhanced levels of the IL-17-associated transcription factor retinoid-related orphan receptor-γt (ROR-γt). Strikingly, these Th17-promoting signals critically depend on CD5-induced elevation of IL-23 receptor (IL-23R) expression. The present data favor the novel concept that alternative costimulation via CD5, rather than classic costimulation via CD28, primes naive T cells for stable Th17 development through promoting the expression of IL-23R.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD5 Antigens/immunology , Receptors, Interleukin/immunology , Th17 Cells/immunology , Adult , CD28 Antigens/immunology , CD28 Antigens/metabolism , CD3 Complex/immunology , CD3 Complex/metabolism , CD4-Positive T-Lymphocytes/cytology , CD5 Antigens/metabolism , Cell Differentiation/immunology , Gene Expression/immunology , Humans , Interleukin-17/genetics , Interleukin-17/immunology , Interleukin-17/metabolism , Nuclear Receptor Subfamily 1, Group F, Member 3/genetics , Nuclear Receptor Subfamily 1, Group F, Member 3/immunology , Nuclear Receptor Subfamily 1, Group F, Member 3/metabolism , Receptors, Interleukin/genetics , STAT3 Transcription Factor/immunology , STAT3 Transcription Factor/metabolism , Signal Transduction/immunology , Th17 Cells/cytology , Transcription, Genetic/immunology
3.
J Histochem Cytochem ; 54(12): 1425-35, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16957167

ABSTRACT

During germinal center (GC) reactions, B-lymphocytes with high-affinity B-cell receptors are selected. Regulation of apoptosis is a key process in selecting such wanted B-cells and in eliminating B-cells with unwanted specificities. In this paper, we show that apoptosis in human GC B-cells involves lysosomal destabilization, which is strictly controlled by caspase-8 activity, but not by caspase-9 activity. Ligation of CD40 provides resistance to lysosomal destabilization. Experimental lysosomal rupture by the lysosomotropic drug O-methyl-l-serine dodecylamide hydrochloride (MSDH) induces apoptosis in GC B-cells, including phosphatidyl serine exposure, mitochondrial inactivation, and DNA fragmentation. These apoptotic features occur in the absence of caspase-3 activity. Follicular dendritic cells (FDCs) protect binding B-lymphocytes from lysosomal destabilization, in both the absence and the presence of MSDH. Our study demonstrates that lysosomal leakage induces apoptosis of GC B-cells in a caspase-3-independent manner and that high-affinity binding to FDCsprevents lysosomal leakage and apoptosis in GC B-cells.


Subject(s)
Apoptosis/physiology , B-Lymphocytes/metabolism , Germinal Center/metabolism , Lysosomes/metabolism , Amides/pharmacology , Apoptosis/drug effects , B-Lymphocytes/cytology , B-Lymphocytes/drug effects , CD40 Antigens/metabolism , Caspase 3/metabolism , Caspase 8/metabolism , Cells, Cultured , DNA Fragmentation/drug effects , Dendritic Cells, Follicular/metabolism , Germinal Center/cytology , Humans , Lysosomes/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , Phosphatidylserines/metabolism , Serine/analogs & derivatives , Serine/pharmacology
4.
Nat Commun ; 5: 5444, 2014 Nov 13.
Article in English | MEDLINE | ID: mdl-25392121

ABSTRACT

M2 macrophages suppress inflammation in numerous disorders, including tumour formation, infection and obesity. However, the exact role of M2 macrophages in the context of several other diseases is still largely undefined. We here show that human M2 macrophages promote inflammation instead of suppressing inflammation on simultaneous exposure to complexed IgG (c-IgG) and TLR ligands, as occurs in the context of diseases such as rheumatoid arthritis (RA). c-IgG-TLR ligand co-stimulation of M2 macrophages selectively amplifies production of pro-inflammatory cytokines TNF-α, IL-1ß and IL-6 and promotes Th17 responses, which all play a critical role in RA pathology. Induction of pro-inflammatory cytokines on c-IgG co-stimulation mainly depends on Fc gamma receptor IIa (FcγRIIa), which selectively amplifies cytokine gene transcription and induces caspase-1 activation. These data indicate that FcγR-TLR cross-talk may be targeted for treatment to attenuate inflammation in RA, by restoring the anti-inflammatory function of M2 macrophages.


Subject(s)
Inflammation/physiopathology , Interleukin-1beta/physiology , Interleukin-6/physiology , Macrophages/physiology , Receptor Cross-Talk/physiology , Receptors, IgG/physiology , Tumor Necrosis Factor-alpha/physiology , Caspase 1/metabolism , Enzyme Activation/physiology , Gene Expression Regulation/physiology , Humans , Interleukin-1beta/biosynthesis , Interleukin-6/biosynthesis , Macrophages/metabolism , Receptors, IgG/metabolism , Th17 Cells/physiology , Tumor Necrosis Factor-alpha/biosynthesis
5.
Clin Exp Metastasis ; 26(3): 171-8, 2009.
Article in English | MEDLINE | ID: mdl-19067186

ABSTRACT

Cancer progression is facilitated by blood coagulation. Anticoagulants, such as Hirudin and low molecular weight heparins (LMWHs), reduce metastasis mainly by inhibition of thrombin formation and L- and P-selectin-mediated cell-cell adhesion. It is unknown whether the effects are dependent on cancer cell type. The effects of anticoagulants on tumor development of K1735 and B16 melanoma cells and CT26 colon cancer cells were investigated in mouse lung. Tumor load was determined noninvasively each week up to day 21 in all experiments using bioluminescence imaging. Effects of anticoagulants on tumor development of the three cell lines were correlated with the fibrin/fibrinogen content in the tumors, expression of tissue factor (TF), protease activated receptor (PAR)-1 and -4 and CD24, a ligand of L- and P-selectins. Hirudin inhibited tumor development of B16 cells in lungs completely but did not affect tumor growth of K1735 and CT26 cells. Low molecular weight heparin did not have an effect on K1735 melanoma tumor growth either. TF and PAR-4 expression was similar in the three cell lines. PAR-1 and CD24 were hardly expressed by K1735, whereas CT26 cells expressed low levels and B16 high levels of PAR-1 and CD24. Fibrin content of the tumors was not affected by LMWH. It is concluded that effects of anticoagulants are dependent on cancer cell type and are correlated with their CD24 and PAR-1 expression.


Subject(s)
Anticoagulants/pharmacology , Lung Neoplasms/pathology , Animals , Anticoagulants/therapeutic use , Blood Coagulation/drug effects , CD24 Antigen/metabolism , Cell Line, Tumor , Fibrin/metabolism , Fibrinogen/metabolism , Heparin, Low-Molecular-Weight/pharmacology , Heparin, Low-Molecular-Weight/therapeutic use , Hirudins/pharmacology , Lung Neoplasms/blood supply , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasm Transplantation , P-Selectin/metabolism , Receptor, PAR-1/metabolism , Thromboplastin/biosynthesis , Transplantation, Heterologous
SELECTION OF CITATIONS
SEARCH DETAIL